Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
Related Stories
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 6 wks
Mass spectrometry platform could cut drug discovery to hours / 2 months
Merck and Moderna report positive phase‑3 melanoma vaccine results / 10 days
Belzutifan plus lenvatinib outperforms cabozantinib in advanced RCC / 11 days
First patient enrolled in AACR-ADOPT-GEA gastroesophageal cancer trial / 22 days
Mass release of next‑generation tumor organoids accelerates research / 22 days
Phase 1 trial shows cevostamab activity in relapsed multiple myeloma / 5 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Pediatric Oncology, Hearing Loss, Clinical Trials and look for the RSS link.
StackHealth Time Machine